000284767 001__ 284767
000284767 005__ 20240229155055.0
000284767 0247_ $$2doi$$a10.1186/s12916-023-03104-1
000284767 0247_ $$2pmid$$apmid:37833736
000284767 0247_ $$2pmc$$apmc:PMC10576353
000284767 0247_ $$2altmetric$$aaltmetric:155395871
000284767 037__ $$aDKFZ-2023-02078
000284767 041__ $$aEnglish
000284767 082__ $$a610
000284767 1001_ $$aNimptsch, Katharina$$b0
000284767 245__ $$aProspective and Mendelian randomization analyses on the association of circulating fatty acid binding protein 4 (FABP-4) and risk of colorectal cancer.
000284767 260__ $$aHeidelberg [u.a.]$$bSpringer$$c2023
000284767 3367_ $$2DRIVER$$aarticle
000284767 3367_ $$2DataCite$$aOutput Types/Journal article
000284767 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1697525301_8572
000284767 3367_ $$2BibTeX$$aARTICLE
000284767 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000284767 3367_ $$00$$2EndNote$$aJournal Article
000284767 520__ $$aFatty acid binding protein 4 (FABP-4) is a lipid-binding adipokine upregulated in obesity, which may facilitate fatty acid supply for tumor growth and promote insulin resistance and inflammation and may thus play a role in colorectal cancer (CRC) development. We aimed to investigate the association between circulating FABP-4 and CRC and to assess potential causality using a Mendelian randomization (MR) approach.The association between pre-diagnostic plasma measurements of FABP-4 and CRC risk was investigated in a nested case-control study in 1324 CRC cases and the same number of matched controls within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. A two-sample Mendelian randomization study was conducted based on three genetic variants (1 cis, 2 trans) associated with circulating FABP-4 identified in a published genome-wide association study (discovery n = 20,436) and data from 58,131 CRC cases and 67,347 controls in the Genetics and Epidemiology of Colorectal Cancer Consortium, Colorectal Cancer Transdisciplinary Study, and Colon Cancer Family Registry.In conditional logistic regression models adjusted for potential confounders including body size, the estimated relative risk, RR (95% confidence interval, CI) per one standard deviation, SD (8.9 ng/mL) higher FABP-4 concentration was 1.01 (0.92, 1.12) overall, 0.95 (0.80, 1.13) in men and 1.09 (0.95, 1.25) in women. Genetically determined higher FABP-4 was not associated with colorectal cancer risk (RR per FABP-4 SD was 1.10 (0.95, 1.27) overall, 1.03 (0.84, 1.26) in men and 1.21 (0.98, 1.48) in women). However, in a cis-MR approach, a statistically significant association was observed in women (RR 1.56, 1.09, 2.23) but not overall (RR 1.23, 0.97, 1.57) or in men (0.99, 0.71, 1.37).Taken together, these analyses provide no support for a causal role of circulating FABP-4 in the development of CRC, although the cis-MR provides some evidence for a positive association in women, which may deserve to be investigated further.
000284767 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000284767 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000284767 650_7 $$2Other$$aColorectal cancer
000284767 650_7 $$2Other$$aFABP-4
000284767 650_7 $$2Other$$aMendelian randomization
000284767 7001_ $$aAleksandrova, Krasimira$$b1
000284767 7001_ $$aPham, Thu Thi$$b2
000284767 7001_ $$aPapadimitriou, Nikos$$b3
000284767 7001_ $$aJanke, Jürgen$$b4
000284767 7001_ $$aChristakoudi, Sofia$$b5
000284767 7001_ $$aHeath, Alicia$$b6
000284767 7001_ $$aOlsen, Anja$$b7
000284767 7001_ $$aTjønneland, Anne$$b8
000284767 7001_ $$aSchulze, Matthias B$$b9
000284767 7001_ $$0P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aKatzke, Verena$$b10$$udkfz
000284767 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b11$$udkfz
000284767 7001_ $$avan Guelpen, Bethany$$b12
000284767 7001_ $$aHarbs, Justin$$b13
000284767 7001_ $$aPalli, Domenico$$b14
000284767 7001_ $$aMacciotta, Alessandra$$b15
000284767 7001_ $$aPasanisi, Fabrizio$$b16
000284767 7001_ $$aYohar, Sandra Milena Colorado$$b17
000284767 7001_ $$aGuevara, Marcela$$b18
000284767 7001_ $$aAmiano, Pilar$$b19
000284767 7001_ $$aGrioni, Sara$$b20
000284767 7001_ $$aJakszyn, Paula Gabriela$$b21
000284767 7001_ $$aFigueiredo, Jane C$$b22
000284767 7001_ $$aSamadder, N Jewel$$b23
000284767 7001_ $$aLi, Christopher I$$b24
000284767 7001_ $$aMoreno, Victor$$b25
000284767 7001_ $$aPotter, John D$$b26
000284767 7001_ $$aSchoen, Robert E$$b27
000284767 7001_ $$aUm, Caroline Y$$b28
000284767 7001_ $$aWeiderpass, Elisabete$$b29
000284767 7001_ $$aJenab, Mazda$$b30
000284767 7001_ $$aGunter, Marc J$$b31
000284767 7001_ $$aPischon, Tobias$$b32
000284767 773__ $$0PERI:(DE-600)2131669-7$$a10.1186/s12916-023-03104-1$$gVol. 21, no. 1, p. 391$$n1$$p391$$tBMC medicine$$v21$$x1741-7015$$y2023
000284767 909CO $$ooai:inrepo02.dkfz.de:284767$$pVDB
000284767 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)fb68a9386399d72d84f7f34cfc6048b4$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000284767 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000284767 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000284767 9141_ $$y2023
000284767 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T09:07:15Z
000284767 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T09:07:15Z
000284767 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Open peer review$$d2023-05-02T09:07:15Z
000284767 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-09-03
000284767 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-09-03
000284767 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-09-03
000284767 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-09-03
000284767 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-09-03
000284767 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBMC MED : 2022$$d2023-10-25
000284767 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-10-25
000284767 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-10-25
000284767 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-10-25
000284767 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search$$d2023-10-25
000284767 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC$$d2023-10-25
000284767 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-10-25
000284767 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-10-25
000284767 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-10-25
000284767 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-10-25
000284767 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bBMC MED : 2022$$d2023-10-25
000284767 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000284767 980__ $$ajournal
000284767 980__ $$aVDB
000284767 980__ $$aI:(DE-He78)C020-20160331
000284767 980__ $$aUNRESTRICTED